Shane Eberhardt
Psychiatric/Mental Health · Burlington, IANPI 1992402655
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 482 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,984, 2.3 times the $1,277 reported in 2023. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$970
- Teva Pharmaceuticals USA, Inc.$911
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$804
- Neurocrine Biosciences, Inc.$663
- Alkermes, Inc.$660
- Otsuka America Pharmaceutical, Inc.$656
- plus $2K from 12 others
What the payments were for
- Food & beverage$6,69896%
- Education$3054%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $970 |
| Teva Pharmaceuticals USA, Inc. | 50 | $911 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $804 |
| Neurocrine Biosciences, Inc. | 51 | $663 |
| Alkermes, Inc. | 45 | $660 |
| Otsuka America Pharmaceutical, Inc. | 35 | $656 |
| Lundbeck LLC | 63 | $642 |
| E.r. Squibb & Sons, L.L.C. | 24 | $503 |
| Johnson & Johnson | 38 | $454 |
| Vanda Pharmaceuticals Inc. | 17 | $351 |
| Axsome Therapeutics, Inc. | 8 | $212 |
| Corium, LLC | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Harmony Biosciences LLC | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Pfizer | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,003 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 54 | $76,902 |
| Invega SustennaPaliperidone Palmitate | 20 | $65,799 |
| VraylarCariprazine Hcl | 27 | $30,726 |
| TrintellixVortioxetine Hydrobromide | 19 | $9,332 |
| Lisdexamfetamine Dimesylate | 13 | $2,908 |
| Paliperidone ErPaliperidone | 17 | $1,450 |
| Hydroxyzine Hcl | 39 | $1,171 |
| Duloxetine Hcl | 65 | $1,133 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $1,108 |
| Buspirone Hcl | 60 | $1,083 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 12 | $1,032 |
| Chlorpromazine Hcl | 12 | $917 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $903 |
| Clozapine | 42 | $750 |
| Aripiprazole | 36 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $656 | $76,90254 claims |
| Johnson & JohnsonInvega Sustenna | $454 | $65,79920 claims |
| AbbVieVraylar | $970 | $30,72627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $29 | $9,33219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Burlington
- Gloria McMillanBurlington$6K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
- Amy MorinCedar Rapids$24K
- Jenna BerendzenCedar Falls$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.